We're thrilled to announce the Anaqua and PatSnap partnership. Together, we'll combine our cutting-edge technologies and capabilities to enable best practices in the management of Intellectual Property for our Life Science clients.

Anaqua AQX® Pharma helps clients manage the business processes of Pharmaceutical IP Management, while Synapse enables drug discovery through external and competitor AI-powered drug discovery processes. Our integrated solution powers end-to-end Product IP Management including stage gate-driven reviews of changes in the external considerations and environment.

Through this partnership, AQX customers get unlimited access to PatSnap's life sciences innovation intelligence solution, Synapse. Combined, these platforms allow users to uncover associations between diseases, target companies, and drugs while improving R&D and accelerating time to market.

AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
126
K
Drugs & Biologics
48
K
Targets
1
M
Organizations
1
M
/
184
K
Clinical Trials / Results
53
M
Literatures
18
M
Patents
Recent blog posts
Market Analysis of Droperidol in the USA: Regulatory History, Safety Risks, and Reintroduction Pathways
Drug Insights
6 min read
Market Analysis of Droperidol in the USA: Regulatory History, Safety Risks, and Reintroduction Pathways
4 September 2025
Market analysis of Droperidol in the USA — overview of approvals, safety (QT prolongation), patent status, and strategic recommendations for potential reintroduction.
Read →
Market Analysis of Etoricoxib in the USA: Regulatory Barriers and Market Opportunities
Drug Insights
6 min read
Market Analysis of Etoricoxib in the USA: Regulatory Barriers and Market Opportunities
4 September 2025
Etoricoxib, a selective COX-2 inhibitor by Merck, is widely approved outside the USA but remains unapproved domestically. Explore its global presence, patent landscape, clinical data, and regulatory challenges in the US market.
Read →
Market Analysis of Aceclofenac in the USA: Opportunities and Barriers for Market Entry
Drug Insights
6 min read
Market Analysis of Aceclofenac in the USA: Opportunities and Barriers for Market Entry
29 August 2025
Aceclofenac is a widely used NSAID in Europe and China but remains unapproved in the USA. Explore its global approvals, patent landscape, clinical results, and strategies for US market entry.
Read →
Check out our latest report
May 2025 Patent  Highlights

May 2025 Patent Highlights

1,Vertex continues to focus on the field of pain 2,Monte Rosa's CDK2 molecular glue degraders 3,Eisbach's ALC1 inhibitor 4,Roche's tri-complex inhibitors 5,Eli Lilly’s CRHR2 peptide agonists 6,LP(a) inhibitor from CSPC is better?

JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics

JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics

This report features four highly representative and innovative therapeutics recently profiled in the JMC Annotation column (submitted before December 2024 and with no clinical failure reported to date). The selection spans a diverse range of modalities, including covalent inhibitors, receptor-selective agonists, and CNS-penetrant compounds. The drugs are being developed by leading pharmaceutical and biotech companies such as Chiesi Farmaceutici S.p.A., Galapagos, Scorpion Therapeutics, and AstraZeneca.Through a systematic examination of the R&D paths of these compounds, this report aims to uncover their therapeutic potential, while also offering insight into their commercial prospects and developmental challenges.

Global Drug R&D Express (February 2025)

Global Drug R&D Express (February 2025)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of February, totaling 120 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.